STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.

Collegium Pharmaceutical forecasts 2025 product revenues of $735-$750 million, with adjusted EBITDA of $435-$450 million. Collegium Pharmaceutical, Inc. has provided its financial guidance for ...

Investors in Collegium Pharmaceutical, Inc. COLL need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $20 Put had some of the ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price target of $46.00. Discover outperforming stocks and ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with a price target of $50.00. Discover outperforming ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue.

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...